Identifying EEG-biomarkers of target engagement by intramuscular ketamine in the treatment of acute suicidality
2020 Young Investigator Grant
Amount Awarded: $90,000
Focus Areas: Clinical Treatment Studies, Neurobiological Studies
Matthew Klein, M.D., Ph.D.
Mount Sinai School of Medicine
Mentor: Murray Stein, M.D., MPH, University of California, San Diego
Inside the Research
Ketamine is increasingly used as a rapid antidepressant, and there is growing evidence that ketamine may have additional anti-suicidal properties distinct from its effects on depression. Patterns of electrical activity in the brain will be studied to determine intramuscular ketamine’s effectiveness in treating acute suicidal thoughts and behaviors. This work seeks to inform an understanding of the mechanism of ketamine’s effects on suicidal ideation and identify whether treatment responses can be predicted from brain activity.